Vascular Endothelial Growth Factor (VEGF) Inhibitor Market to Hit $29.9B by 2033 on Cancer, Aging Demographics – SRI

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and ...

Fiber-optic tear test spots LCN1 and VEGF together for diabetic retinopathy

Tear fluid is emerging as an attractive source of diagnostic information because it can be collected easily and noninvasively ...
Ophthalmology Times

Q&A: KSI-101: A new dual anti-interleukin-6 and anti-VEGF protein for treating macular edema associated with inflammation

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...